Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports

Rituximab is a chimeric monoclonal antibody specific for human CD20 that causes selective transient depletion of the CD20+ B‐cell subpopulation. We report the first case of systemic lupus erythematosus (SLE) pneumonitis resistant to conventional treatments that responded well to rituximab and review...

Full description

Saved in:
Bibliographic Details
Published in:Internal medicine journal 2006-04, Vol.36 (4), p.260-262
Main Authors: Lim, S. W., Gillis, D., Smith, W., Hissaria, P., Greville, H., Peh, C. A.
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
B-cell depletion
Biological and medical sciences
Exercise Tolerance - drug effects
Female
General aspects
Humans
Immunologic Factors - therapeutic use
Lupus Erythematosus, Systemic - complications
Lupus Erythematosus, Systemic - drug therapy
Medical sciences
Pneumonia - drug therapy
Pneumonia - etiology
pneumonitis
Rituximab
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
systemic autoimmune disease
systemic lupus erythematosus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rituximab is a chimeric monoclonal antibody specific for human CD20 that causes selective transient depletion of the CD20+ B‐cell subpopulation. We report the first case of systemic lupus erythematosus (SLE) pneumonitis resistant to conventional treatments that responded well to rituximab and review current reports on the use of rituximab in SLE.
ISSN:1444-0903
1445-5994
DOI:10.1111/j.1445-5994.2006.01055.x